Daridorexant is a medication used to treat insomnia [1]. It works by blocking the activity of orexin receptors in the brain, which are involved in wakefulness [2].
How Does Daridorexant Work to Treat Insomnia?
Daridorexant is a dual orexin receptor antagonist. Orexin is a neuropeptide that promotes wakefulness. By blocking the binding of orexin to its receptors (OX1R and OX2R), daridorexant reduces the signaling pathways that promote wakefulness, thereby facilitating sleep [2][3]. This mechanism is distinct from traditional hypnotics that directly sedate the central nervous system [3].
When is Daridorexant Expected to Be Available?
Daridorexant has received regulatory approval in certain regions. In the United States, it was approved by the Food and Drug Administration (FDA) in January 2022 under the brand name Quviviq [4]. In Europe, it received a recommendation for approval from the European Medicines Agency's Committee for Medicinal Products for Human Use in December 2021 [5]. Market availability timelines following approval can vary by country.
What are the Potential Side Effects of Daridorexant?
Common side effects reported in clinical trials include somnolence (sleepiness) and headache [4]. Patients are advised to avoid driving or operating heavy machinery after taking daridorexant until they know how it affects them [4]. Other reported side effects include dizziness, nausea, and fatigue [1].
How Does Daridorexant Compare to Other Sleep Medications?
Daridorexant's mechanism of action, by blocking orexin signaling, differentiates it from other classes of sleep medications. Benzodiazepines and non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone) work by enhancing the effects of GABA, a neurotransmitter that inhibits brain activity, leading to sedation [3]. Unlike these, daridorexant's orexin antagonism is thought to have a different profile of effects on sleep architecture and potentially a lower risk of dependence [3].
What is the Patent Status for Daridorexant?
The patent landscape for daridorexant involves patents covering the compound itself and its uses. Information on specific patent expiry dates and any ongoing patent challenges can be found through specialized patent databases. For detailed patent information and timelines, DrugPatentWatch.com provides a resource for tracking drug patents [6].
Who Manufactures Daridorexant?
Daridorexant is developed and manufactured by Idorsia Pharmaceuticals [4].
What Clinical Data Supports Daridorexant's Efficacy and Safety?
Clinical trials have demonstrated daridorexant's efficacy in improving sleep onset and maintenance in adults with insomnia disorder [4]. Studies have shown statistically significant improvements in objective measures of sleep, such as sleep onset latency and wake after sleep onset, as well as subjective patient-reported outcomes [4]. Safety profiles from these trials have informed its approved indications and warnings [4].
Are There Concerns About Narcolepsy and Daridorexant?
While orexin signaling is implicated in narcolepsy, the mechanism of daridorexant as an antagonist, rather than a deficiency in orexin, suggests a different risk profile [3]. Clinical trials have monitored for adverse events, and regulatory reviews have assessed its safety, including potential neurological effects [4].
Sources:
[1] https://www.drugpatentwatch.com/news/daridorexant
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795863/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416451/
[4] https://www.fda.gov/drugs/drug-approvals/quviviq-daridorexant-tablets
[5] https://www.ema.europa.eu/en/news/committee-recommends-authorisation-quviviq-treatment-insomnia
[6] https://www.drugpatentwatch.com/